Several factors were associated with an increased risk of UTI recurrence. These included antibiotic exposure prior to treatment, pyelonephritis on diagnosis date, having a follow-up visit during antibiotic treatment, receiving parenteral antibiotics.
Results showed that sulopenem failed to demonstrate non-inferiority to ertapenem (difference of 4.7%; 95% CI: -10.3, 1.0); 85.5% of patients in the sulopenem arm had a clinical response vs 90.2% of the ertapenem group.
The FDA’s Antimicrobial Drugs Advisory Committee voted 14 to 2 in favor of approval of cefiderocol for the treatment of complicated urinary tract infections, including pyelonephritis, in patients with limited or no alternative treatment options.
No net benefit seen for screening, treatment of asymptomatic bacteriuria for nonpregnant adults
Findings seen in propensity-matched cohorts versus receipt of DPP-4 inhibitors or GLP-1 agonists
The FDA has issued a Complete Response Letter to Nabriva Therapeutics regarding the New Drug Application for Contepo (fosfomycin).
The USPSTF recommends screening pregnant women for asymptomatic bacteriuria (ASB) but not nonpregnant women or men.
Nondihydropyridine calcium channel blockers (non-DHP CCBs) appear to reduce proteinuria in patients with diabetic kidney disease
The Food and Drug Administration has expanded the approval of Avycaz (ceftazidime and avibactam) to include pediatric patients aged ≥3 months for the treatment of complicated intra-abdominal infections, used in combination with metronidazole, and for complicated urinary tract infections.
Recommendations have been developed for use of polymyxins, focusing on polymyxin B and polymyxin E (colistin); the guidelines were recently published in Pharmacotherapy.
